



ASX ANNOUNCEMENT

Lumos Secures 100% U.S. Medicare Reimbursement Recognition for FebriDx®

Key Highlights

- Lumos has now secured 100% reimbursement recognition for FebriDx® from all Medicare Administration Contractors (MAC) at US\$41.38 per test as listed in the CMS Clinical Lab Fee Schedule (CLFS).
- National Government Services (NGS), seventh and final MAC to link FebriDx with the CLFS. Responsible for Illinois, Minnesota and Wisconsin, plus the New England and New York regions.
- Focus now turns to assisting MACs to develop written policy, ensuring timely and efficient reimbursement claims management.
- Lumos partner, PRO-spectus, will help the MACs and other payors integrate coverage into their policies.

MELBOURNE, Australia 21 November 2025 – Lumos Diagnostics (ASX: LDX), (“Lumos” or the “Company”) a leader in rapid, point-of-care diagnostic technologies, is pleased to announce that it has secured Medicare reimbursement recognition from the seventh and final of the Medicare Administrative Contractors (MAC), National Government Services (NGS). FebriDx was recently linked to the Clinical Lab Fee Schedule from NGS.

NGS is responsible for managing Medicare payments in the states of Illinois, Minnesota and Wisconsin, plus the New England and New York regions.


With the inclusion of NGS, to the previously announced coverage from CGS (ASX: 27 May 2025), Novitas and Palmetto (ASX: 17 April 2025), First Coast Service Options and Noridian Healthcare Solutions (ASX: 23 April 2025), and WPS Health Solutions (ASX: 19 May 2025) Lumos now has Medicare reimbursement recognition from all seven MACs, representing over 100% of the total US Medicare payment coverage. Medicare comprises approximately 20%–24% of the U.S. payor mix.

The next step toward meaningful U.S. adoption of FebriDx is to work with each MAC to establish a formal written policy, delivering greater clarity and predictability and enabling more efficient reimbursement processing.

Full Medicare coverage also provides meaningful benefits for Medicare Advantage (MA) and Medicaid plans, as these payors frequently reference Centers for Medicare and Medicaid Services (CMS) fee

schedules when establishing their own reimbursement frameworks. Over time, PRO-spectus will closely engage with these and other private payors to support the integration of this coverage into their internal processes.

Map of U.S. MAC Jurisdictions



Commenting on the announcement, Doug Ward, Managing Director of Lumos Diagnostics said: *“Securing reimbursement from all seven MAC’s is a landmark achievement for Lumos and helps position FebriDx for broad adoption across the U.S. healthcare system. Full Medicare recognition not only unlocks access across all regions but also paves the way for wider uptake through Medicare Advantage, Medicaid and private payors. We look forward to working closely with our partners to support the integration of this coverage and ensure FebriDx reaches the clinicians and patients who will benefit most.”*

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contacts:

Haley Chartres – Australia
H^CK Director
haley@hck.digital
+61 423 139 163

Investor Contact:

George Kopsiaftis
IR Specialist, IR Department
ir@lumosdiagnostics.com
+61 409 392 687

Company Registered Office:

Lumos Diagnostics Holdings Ltd
Suite 2, Level 11
385 Bourke Street
Melbourne VIC 3000
info@lumosdiagnostics.com
+61 3 9087 1598